The UK and US have agreed to a landmark bilateral deal that will preserve no import taxes on British drug exports being sold in the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This move secures that tariffs on these key products will stay at zero for a timeframe of 36 months.
This deal comes after previous warnings to significantly raise tariffs on patented pharmaceutical products, with increases floated up to 100%.
"This deal with the United Kingdom strengthens the international landscape for cutting-edge drugs and brings much-needed balance to transatlantic pharmaceutical trade," a release said.
Economic Impact
Drugs constitute one of the Britain's most significant export categories to the US, which is by far the biggest buyer for leading British pharmaceutical firms.
Trade data show that in the one-year period to the end of last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This figure accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee protects work, increases investment and facilitates the UK to establish itself as a international leader for life sciences," a government official remarked.
Specific UK Commitments
The pact entails several notable pledges from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to double total public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments were more than twenty percent.
Broader Context
The deal comes amid a long-running tension between the sector and the UK government over medicine costs and approval rates.
This friction were intensified by arguments that US consumers were paying a premium for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward US facilities.
One official acknowledged that the NHS had to increase expenditure on drugs, noting that its spending on drugs had decreased as a proportion of its overall budget over the past decade.
